Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Can a mammogram help identify heart disease? - 2Space Condos to Lift Your Metropolitan Living
- 3Inflammatory Merz remarks on migrants' violence against women slammed
- 4Newly Built Sichuan Hydropower Bridge Collapses Into River Months After Opening
- 5'Euphoria' Season 3 trailer includes Eric Dane's final appearance, Jacob Elordi and Sydney Sweeney at the altar and Rue's 'Breaking Bad' era
- Chicago reports first rabies-positive dog in 61 years. What we know.
- Recalled "super greens" supplement linked to dozens of salmonella cases, CDC says
- ADHD drugs work, but not the way experts thought
- How did I get my own unique set of fingerprints?
- Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- As her kidneys fail and time runs short, this activist fights to decriminalize euthanasia in Mexico
- Mother and Stepson Rescued After Being Swept Over 6 Miles in Paddleboarding Mishap
- How a rare drug made from scientists' blood saves babies from botulism
- 2026 will be the year NASA astronauts fly around the moon again — if all goes to plan
